¼¼°èÀÇ ½Ç½Ã°£ PCR ½ÃÀåÀº 2024³â¿¡ 43¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 4.56%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
½Ç½Ã°£ PCRÀº PCRÀÇ ¿ø¸®¸¦ Àû¿ëÇÑ ºÐÀÚ »ý¹°ÇÐÀÇ ½ÇÇè ±â¼úÀÔ´Ï´Ù. ÀÓ»ó Áø´Ü°ú ¼öÀÇ»ç Áø´Ü, ½Äǰ ¾ÈÀü ºÐ¾ß¿¡¼ ½Ç½Ã°£ PCRÀº ´Ù¾çÇÑ ¹Ì»ý¹°À» °ËÃâ, Á¤·®, µ¿Á¤Çϱâ À§ÇÑ È®¸³µÈ ±â¼ú·Î¼ Å« ÀÎÁö¸¦ ¾ò°í ÀÖ½À´Ï´Ù. PCRÀÇ ¿ø¸®´Â °Ñº¸±â¿¡ ´Ü¼øÇÑ °Íó·³ º¸ÀÌÁö¸¸, ÀÌ ±â¼úÀÇ °³¹ßÀÚ¿Í »ç¿ëÀÚ´Â Á¤·® PCR(qPCR)°ú °ü·ÃµÈ ƯÁ¤ ¹®Á¦¸¦ ÀνÄÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, WHO2024¿¡ µû¸£¸é, CepheidÀÇ Xpert Mpox ½Ç½Ã°£ PCR °Ë»ç´Â 10¿ù 25ÀÏ ±ä±Þ »ç¿ë ¸ñ·Ï(EUL)¿¡ °Ô½ÃµÇ¾ú½À´Ï´Ù. GeneXpert ½Ã½ºÅÛÀ» À§ÇØ ¼³°èµÈ ÀÌ °Ë»ç´Â »ç¿ëÇϱ⠽±°í ¿ÏÀüÈ÷ ÀÚµ¿ÈµÇ¾î 40ºÐ À̳»¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â ¿ø¼þÀ̵Îâ ¹ÙÀÌ·¯½º IIÇü DNA¸¦ °ËÃâÇÏ¸ç ºÐ»êÇü ´Ï¾îPOC(Point of Care) Áø´ÜÀ» Áö¿øÇÕ´Ï´Ù.
½ÃÀå °³¿ä | |
---|---|
¿¹Ãø ±â°£ | 2026-2030³â |
½ÃÀå ±Ô¸ð : 2024³â | 43¾ï 3,000¸¸ ´Þ·¯ |
½ÃÀå ±Ô¸ð : 2030³â | 56¾ï 1,000¸¸ ´Þ·¯ |
CAGR 2025-2030³â | 4.56% |
±Þ¼ºÀå ºÎ¹® | ÀÓ»ó Áø´Ü |
ÃÖ´ë ½ÃÀå | ºÏ¹Ì |
ÀÌ·¯ÇÑ ¿ì·Á´Â ¿ë¾î¿Í Á¤ÀÇÀÇ Á¤È®ÇÑ »ç¿ë, PCR ¿ø¸®ÀÇ Á¾ÇÕÀûÀÎ ÀÌÇØ, µ¥ÀÌÅÍ ºÐ¼® ¹× Á¦½Ã¿Í °ü·ÃµÈ °úÁ¦, ´Ù¾çÇÑ ¹Ì»ý¹° Áø´Ü ÀÀ¿ë ºÐ¾ß¿¡¼ qPCRÀÇ ÇÑ°è µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. qPCRÀÇ ¼º´ÉÀ» ¼³¸íÇϱâ À§ÇØ ÇʼöÀûÀÎ ÆÄ¶ó¹ÌÅ͵µ °í·ÁÇØ¾ß ÇÕ´Ï´Ù. ½Ç½Ã°£ PCR¿¡´Â PCR »ê¹°À» °ËÃâÇÏ´Â µ¥ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â µÎ °¡Áö ±â¼úÀÌ ÀÖ½À´Ï´Ù. ù ¹øÂ° ¹æ¹ýÀº ¸ðµç ÀÌÁß °¡´Ú DNA¿¡ »ðÀԵǴ ºñƯÀÌÀû Çü±¤Áõ¹éÁ¦¸¦ »ç¿ëÇÏ´Â °ÍÀÔ´Ï´Ù. µÎ ¹øÂ° Á¢±Ù¹ýÀº Çü±¤ ¸®Æ÷ÅͷΠǥÁöµÈ ¿Ã¸®°í ´ºÅ¬·¹¿ÀŸÀ̵åÀÎ ¼¿ ƯÀÌÀû DNA ÇÁ·Îºê¸¦ »ç¿ëÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Îºê´Â »óº¸ÀûÀÎ ¼¿°úÀÇ ÇÏÀ̺긮µåÈ ÈÄ¿¡¸¸ °ËÃâÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÑ ¼¼ºÎ »çÇ×À» ´Ù·ç¸é¼ ¿¬±¸ÀÚ¿Í ½Ç¹«ÀÚ´Â °¢ ºÐ¾ß¿¡¼ ½Ç½Ã°£ PCRÀ» Á¤È®Çϰí È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç ºÐÀÚÁø´Ü ¹× ¹Ì»ý¹° ºÐ¼®ÀÇ ¹ßÀü¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
´Ù¾çÇÑ Áúº´°ú À¯Àü¼º Áúȯ Áõ°¡
ÀåºñÀÇ ³ôÀº ºñ¿ë
ÀÚµ¿È ¹× ·Îº¿ °øÇаúÀÇ ÅëÇÕ
Global Real Time PCR Market was valued at USD 4.33 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.56% through 2030F. Real-time polymerase chain reactions (PCR) are molecular biology laboratory techniques that build upon the principles of PCR. In the fields of clinical and veterinary diagnostics, as well as food safety, real-time PCR has gained significant recognition as a well-established technology for detecting, quantifying, and identifying various microbial agents. While the PCR principle may seem straightforward, it is crucial for creators and users of this technology to be aware of specific concerns associated with quantitative PCR (qPCR). For instance, according to WHO 2024, the Xpert Mpox real-time PCR test by Cepheid was listed under its Emergency Use Listing (EUL) on October 25. Designed for GeneXpert systems, the test is easy to use, fully automated, and delivers results in under 40 minutes. It detects monkeypox virus clade II DNA and supports decentralized, near-point-of-care diagnostics.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 4.33 Billion |
Market Size 2030 | USD 5.61 Billion |
CAGR 2025-2030 | 4.56% |
Fastest Growing Segment | Clinical Diagnostics |
Largest Market | North America |
These concerns include the accurate use of terminology and definitions, a comprehensive understanding of the PCR principle, challenges related to data interpretation and presentation, as well as limitations of qPCR in different microbial diagnostic applications. Parameters that are vital for describing qPCR performance also need to be taken into consideration. In real-time PCR, there are two commonly used techniques for detecting PCR products. The first technique involves non-specific fluorescent dyes that intercalate with any double-stranded DNA. The second technique utilizes sequence-specific DNA probes, which are oligonucleotides labeled with fluorescent reporters. These probes enable detection only after hybridization with the complementary sequence. By addressing these intricate details, researchers and practitioners can ensure the accurate and effective use of real-time PCR in their respective fields, contributing to advancements in molecular diagnostics and microbial analysis.
Key Market Drivers
Rising Incidences of Different Diseases and Genetic Disorders
A study conducted by the Journal of the Royal Society Interface reveals a significant rise in disease levels since 1980. It indicates that nearly 30% of diseases are responsible for a staggering 80% of outbreaks, highlighting the urgent need for effective disease prevention and management strategies. The genetic disorders have become increasingly prevalent in recent times, posing a major challenge to global healthcare systems. For instance, according to a 2024 article, scientists identified a genetic disorder linked to mutations in the RNU4-2 gene, associated with severe developmental delays. The discovery may affect thousands globally, with hundreds already diagnosed. This breakthrough offers new insights into genetic conditions and potential pathways for diagnosis and treatment.
According to the World Health Organization (WHO), genetic disorders now account for over 28% of hospital admissions and are a leading cause of childhood mortality, contributing to almost 50% of childhood deaths. These statistics underscore the critical importance of prenatal diagnosis and carrier testing for genetic disorders. In this context, quantitative polymerase chain reaction (qPCR) have emerged as the preferred techniques for accurate and reliable genetic testing. qPCR has long played a pivotal role in diagnosing diseases by investigating bacteria and viruses, while dPCR, although still an emerging technology, has demonstrated its ability to enhance the detection of extremely precise gene mutations.
The advancements in real-time PCR technologies have propelled the market forward, opening up new possibilities for improved disease diagnosis, genetic screening, and personalized medicine. As researchers continue to uncover the complexities of the human genome, the demand for innovative PCR solutions is expected to grow, leading to further advancements in the field. The findings of the study emphasize the pressing need for continued research, innovation, and collaboration in the realm of disease prevention and genetic testing. By staying at the forefront of scientific developments, we can strive to mitigate the impact of diseases and genetic disorders, ultimately improving global health outcomes.
Key Market Challenges
High Cost of Instruments
The equipment and tools required for conducting PCR tests, particularly qPCR equipment, are often on the higher end in terms of cost. According to multiple sources, the price range for dPCR or qPCR machinery can vary from $15,000 to well over $100,000, depending on the specific model and features. This significant investment is not limited to the initial purchase alone. There are also ongoing expenses to consider, such as the annual operational costs of cyclers and the cost of universal probe mastermixes.
These hidden costs can accumulate over time and pose challenges to market growth, especially in both developing and developed economies. The considerable financial implications associated with acquiring and maintaining the equipment may deter potential users or limit accessibility, hindering the expansion of PCR testing in various settings.
The costs associated with PCR testing go beyond the equipment itself. Additional expenses can arise from sample preparation, consumables, reagents, and the need for skilled personnel to operate and maintain the equipment. All of these factors contribute to the overall cost and complexity of implementing PCR testing in different healthcare settings. As the demand for PCR testing continues to rise, efforts to address these challenges are crucial. Finding ways to reduce costs, increase affordability, and streamline the process can help make PCR testing more accessible and widespread, ultimately benefiting healthcare systems, researchers, and patients alike.
Key Market Trends
Integration with Automation and Robotics
The integration of real-time polymerase chain reaction (PCR) with automation and robotic systems holds significant promise in increasing efficiency and reducing user-dependent variability across various fields, particularly in clinical diagnostics, high-throughput screening, and large-scale research projects. Automated real-time PCR systems are designed to execute tasks with a high degree of precision and consistency. Robots can accurately dispense reagents, mix samples, and perform thermal cycling, minimizing human errors and ensuring reproducibility of results. This is especially crucial in clinical diagnostics, where accuracy is paramount.
Automated systems can handle a large number of samples simultaneously, significantly increasing throughput. This is particularly valuable in high-throughput screening applications, where hundreds or thousands of samples need to be processed quickly, such as in drug discovery, genomics, or epidemiology studies. Automated systems often incorporate sample tracking and data management software, ensuring full traceability of samples throughout the PCR process. This feature enhances data integrity, minimizes the risk of sample mix-up, and simplifies record-keeping, which is vital in clinical diagnostics and regulatory compliance.
In this report, the Global Real Time PCR Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Real Time PCR Market.
Global Real Time PCR market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: